Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders;Utilisation des immunoglobulines polyclonales intraveineuses dans les pathologies auto-immunes et inflammatoires

Transfusion Clinique et Biologique

Volumn 14, Issue 1, 2007, Pages 63-68

  Graff Dubois, Stéphanie ^a   Sibéril, Sophie ^a   Elluru, Sriramulu ^a,b   Negi, Vir Singh ^c   Delignat, Sandrine ^a   Mouthon, Luc ^d   Lacroix Desmazes, Sébastien ^a   Kazatchkine, Michel D ^a   Bayary, Jagadeesh ^a   Kaveri, Srini V ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^c JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^d Centre de référence pour les vascularites et la sclérodermie systémique ^*  (France)

Author keywords

Autoimmunity; Immune modulation; Inflammation; Intravenous immunoglobulins

Indexed keywords

COMPLEMENT; CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; POLYCLONAL IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; DRUG MECHANISM; HUMAN; IMMUNOCOMPETENCE; IMMUNOREGULATION; INFLAMMATORY DISEASE; SHORT SURVEY;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFLAMMATION;

EID: 34249984436     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2007.04.003     Document Type: Short Survey

References (63)

1. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
2. Jolles S., Sewell W.A., and Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142 (2005) 1-11
3. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553
4. Gold R., Stangel M., and Dalakas M.C. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3 (2007) 36-44
5. Sherer Y., and Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 5 (2006) 153-155
6. Sapir T., Blank M., and Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 1051 (2005) 743-778
7. Sapir T., and Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 29 (2005) 185-199
8. Ghielmetti M., Bellis M., Spycher M.O., Miescher S., and Vergeres G. Gene expression profiling of the effects of intravenous immunoglobulin in human whole blood. Mol Immunol 43 (2006) 939-949
9. Raju R., and Dalakas M.C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128 (2005) 1887-1896
10. Debre M., Bonnet M.C., Fridman W.H., Carosella E., Philippe N., Reinert P., et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342 (1993) 945-949
11. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 37 (2000) 261-266
12. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
13. Kaneko Y., Nimmerjahn F., Madaio M.P., and Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 (2006) 789-797
14. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., and Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 115 (2005) 2914-2923
15. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., and Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12 (2006) 688-692
16. Hamerman J.A., and Lanier L.L. Inhibition of immune responses by ITAM-bearing receptors. Sci STKE (2006) re1
17. Park-Min K.H., Serbina N.V., Yang W., Ma X., Krystal G., Neel B.G., et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26 (2007) 67-78
18. Akilesh S., Petkova S., Sproule T.J., Shaffer D.J., Christianson G.J., and Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113 (2004) 1328-1333
19. Kazatchkine M.D., Dietrich G., Hurez V., Ronda N., Bellon B., Rossi F., et al. V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 139 (1994) 79-107
20. Sherer Y., Levy Y., and Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 39 (2000) 421-426
21. Abedi M.R., Hammarstrom L., Broome U., Angelin B., Smith C.I., and Christensson B. Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Clin Exp Immunol 105 (1996) 266-273
22. Vassilev T., Yamamoto M., Aissaoui A., Bonnin E., Berrih-Aknin S., Kazatchkine M.D., et al. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol 29 (1999) 2436-2442
23. Sami N., Bhol K.C., and Ahmed A.R. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105 (2002) 192-198
24. Sherer Y., and Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2 (2006) 99-106
25. Hoffmann M., Uttenreuther-Fischer M.M., Lerch H., Gaedicke G., and Fischer P. IVIG-bound IgG and IgM cloned by phage display from a healthy individual reveal the same restricted germ-line gene origin as in autoimmune thrombocytopenia. Clin Exp Immunol 121 (2000) 37-46
26. Osei A., Uttenreuther-Fischer M.M., Lerch H., Gaedicke G., and Fischer P. Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin. Arthritis Rheum 43 (2000) 2722-2732
27. Leucht S., Uttenreuther-Fischer M.M., Gaedicke G., and Fischer P. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30 5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Clin Immunol 99 (2001) 18-29
28. Andersson U., Bjork L., Skansen S.U., and Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139 (1994) 21-42
29. Andersson U.G., Bjork L., Skansen-Saphir U., and Andersson J.P. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79 (1993) 211-216
30. Ruiz de Souza V., Carreno M.P., Kaveri S.V., Ledur A., Sadeghi H., Cavaillon J.M., et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 25 (1995) 1267-1273
31. Sharief M., Ingram D., Swash M., and Thompson E. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 52 (1999) 1833-1838
32. Gupta M., Noel G.J., Schaefer M., Friedman D., Bussel J., and Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 21 (2001) 193-199
33. Basta M., Fries L.F., and Frank M.M. High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77 (1991) 376-380
34. Mollnes T.E., Hogasen K., De Carolis C., Vaquero E., Nielsen EW., Fontana L., et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 48 (1998) 312-317
35. Lutz H.U., Stammler P., Jelezarova E., Nater M., and Spath P.J. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 88 (1996) 184-193
36. Lutz H.U., Stammler P., Bianchi V., Trueb R.M., Hunziker T., Burger R., et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103 (2004) 465-472
37. van Schaik I.N., Lundkvist I., Vermeulen M., and Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 12 (1992) 325-334
38. van Schaik I.N., Vermeulen M., and Brand A. In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatry 57 (1994) 15-17
39. Warrington R.J., and Lewis K.E. Biologically active anti-nerve growth factor antibodies in commercial intravenous gammaglobulin. J Autoimmun (2007)
40. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
41. Prasad N.K., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
42. Altznauer F., von Gunten S., Spath P., and Simon HU. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 112 (2003) 1185-1190
43. Marchalonis J.J., Kaymaz H., Dedeoglu F., Schlutter S.F., Yocum D.E., and Edmundson A.B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci U S A 89 (1992) 3325-3329
44. Svenson M., Hansen M.B., Ross C., Diamant M., Rieneck K., Nielsen H., et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in Human IgG preparations. Blood 91 (1998) 2054-2061
45. Bendtzen K., Hansen M.B., Ross C., and Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 19 (1998) 209-211
46. Vassilev T., Gelin C., Kaveri S.V., Zilber M.T., Boumsell L., and Kazatchkine M.D. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins IVIg). Clin Exp Immunol 92 (1993) 369-372
47. Hurez V., Kaveri S.V., Mouhoub A., Dietrich G., Mani J.C., Klatzmann D., et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin IVIg). Ther Immunol 1 (1994) 269-278
48. Kaveri S., Vassilev T., Hurez V., Lengagne R., Cot S., Pouletty P., et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J Clin Invest 97 (1996) 865-869
49. Vassilev T., Kazatchkine M.D., Duong Van Huyen JP., Mekrache M., Bonnin E., Korinth D., et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (Intravenous Immunoglobulin IVIg). Blood 93 (1999) 3624-3631
50. Bouhlal H., Hocini H., Quillent-Gregoire C., Donkova V., Rose S., Amara A., et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 166 (2001) 7606-7611
51. Bayry J., Lacroix-Desmazes S., Donkova-Petrini V., Carbonneil C., Misra N., Lepelletier Y., et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A 101 (2004) 14210-14215
52. Sigman K., Ghibu F., Sommerville W., Toledano B.J., Bastein Y., Cameron L., et al. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 102 (1998) 421-427
53. de Grandmont M.J., Racine C., Roy A., Lemieux R., and Neron S. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101 (2003) 3065-3073
54. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003) 758-765
55. Bayry J., Lacroix-Desmazes S., Delignat S., Mouthon L., Weill B., Kazatchkine M.D., et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 3497-3502
56. Bayry J., Hermine O., Webster D.A., Levy Y., and Kaveri S.V. Common variable immunodeficiency: the immune system in chaos. Trends Mol Med 11 (2005) 370-376
57. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Galicier L., Lepelletier Y., Webster D., et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 104 (2004) 2441-2443
58. Bayry J., Lacroix-Desmazes S., Hermine O., Oksenhendler E., Kazatchkine M.D., and Kaveri S.V. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 118 (2005) 1439-1440
59. Bayry J., Kazatchkine M.D., and Kaveri S.V. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 3 (2007) 120-121
60. Ahmed A.R., Spigelman Z., Cavacini L.A., and Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355 (2006) 1772-1779
61. Hurez V., Kazatchkine M.D., Vassilev T., Ramanathan S., Pashov A., Basuyaux B., et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90 (1997) 4004-4013
62. Bazin R., Lemieux R., and Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 135 (2006) 97-100
63. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673